[
  {
    "objectID": "pages/publications.html",
    "href": "pages/publications.html",
    "title": "Publications",
    "section": "",
    "text": "Updated automatically from OpenAlex using ORCID 0000-0002-4848-4951.\n\nUpdated: 157 works; citations 775; h-index 14."
  },
  {
    "objectID": "pages/publications.html#summary-auto",
    "href": "pages/publications.html#summary-auto",
    "title": "Publications",
    "section": "",
    "text": "Updated automatically from OpenAlex using ORCID 0000-0002-4848-4951.\n\nUpdated: 157 works; citations 775; h-index 14."
  },
  {
    "objectID": "pages/publications.html#publications-recent-first",
    "href": "pages/publications.html#publications-recent-first",
    "title": "Publications",
    "section": "Publications (recent first)",
    "text": "Publications (recent first)\n\n2025: Semiconducting artificial dendritic cells with biocatalytic and radiosensitive iron centers to eradicate radioresistant squamous cell carcinoma. DOI: 10.1016/j.celbio.2025.100277\n2025: Childhood-onset depression and newly diagnosed chronic diseases after age 65: a large longitudinal cohort study. DOI: 10.1186/s12888-025-07494-9\n2025: Prognostic value of systemic inflammation-modified Patient-Generated Subjective Global Assessment in advanced cancers: A large-scale retrospective cohort study. DOI: 10.1007/s00520-025-10010-0\n2025: Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis. DOI: 10.2147/jir.s546584\n2025: Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167). DOI: 10.1007/s00262-025-04162-5\n2025: Randomized, double‐blind phase III trial of a dexamethasone‐free regimen for managing highly emetogenic chemotherapy‐induced nausea and vomiting. DOI: 10.1002/ijc.70069\n2025: Editorial: Opportunities and challenges of head and neck cancer treatment in the era of immune checkpoint inhibitors. DOI: 10.3389/fimmu.2025.1656915\n2025: Systematic inflammation burdens improve the survival prediction value of nutrition assessment in postoperative patients with recurrent or metastatic cancer: A retrospective observational study. DOI: 10.1002/ncp.11336\n2025: Outside Front Cover: Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy (Angew. Chem. 23/2025). DOI: 10.1002/ange.202510019\n2025: Outside Front Cover: Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy (Angew. Chem. Int. Ed. 23/2025). DOI: 10.1002/anie.202510019\n2025: Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors. DOI: 10.3389/fonc.2025.1610079\n2025: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors. DOI: 10.3389/fonc.2025.1539514\n2025: Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study. DOI: 10.1016/j.oraloncology.2024.107161\n2025: Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy. DOI: 10.1001/jamanetworkopen.2025.47590\n2025: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167). DOI: 10.1007/s00262-024-03905-0\n2025: Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy. DOI: 10.1002/ange.202505564\n2025: Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD‐L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma. DOI: 10.1002/hed.28101\n2025: Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy. DOI: 10.1002/anie.202505564\n2025: Association of type 2 diabetes, hypertension, and hyperlipidemia with immune-related adverse events in patients undergoing immune checkpoint inhibitors therapy. DOI: 10.3389/fimmu.2025.1472197\n2025: Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma. DOI: 10.1038/s41392-025-02184-0\n2024: Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis. DOI: 10.7150/jca.103847\n2024: Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.. DOI: 10.1200/jco.2024.42.16_suppl.6046\n2024: Harnessing the Systemic Immunoinflammatory Index as a Potential Predictive Tool for Recurrent or Metastatic Nasopharyngeal Carcinoma Undergoing PD-L1 Inhibitor. DOI: 10.2147/jir.s474162\n2024: Causal effect of gut microbiota on occurrence of herpes zoster and postherpetic neuralgia, and role of Tyzzerella 3. DOI: 10.1186/s40001-024-02106-w\n2024: Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study. DOI: 10.1016/j.oraloncology.2024.107028\n2024: Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta‐analysis. DOI: 10.1111/cen.15027\n2024: Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity. DOI: 10.1186/s40001-024-01741-7\n2024: Serum tumor markers and outcomes in lung cancer patients with brain metastases: a retrospective longitudinal cohort study. DOI: 10.21037/tlcr-24-404\n2024: Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database. DOI: 10.3389/fimmu.2024.1439231\n2024: Characterizing neuroinflammation and identifying prenatal diagnostic markers for neural tube defects through integrated multi-omics analysis. DOI: 10.1186/s12967-024-05051-8"
  },
  {
    "objectID": "pages/publications.html#profiles",
    "href": "pages/publications.html#profiles",
    "title": "Publications",
    "section": "Profiles",
    "text": "Profiles\n\nORCID: https://orcid.org/0000-0002-4848-4951\nPubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Liu+Zheran%5BAuthor%5D"
  },
  {
    "objectID": "pages/orcid.html",
    "href": "pages/orcid.html",
    "title": "ORCID",
    "section": "",
    "text": "ORCID: https://orcid.org/0000-0002-4848-4951\n\nIf you connect ORCID to your publication list (or export your works), we can render a full publications page automatically."
  },
  {
    "objectID": "pages/contact.html",
    "href": "pages/contact.html",
    "title": "Contact",
    "section": "",
    "text": "ORCID: https://orcid.org/0000-0002-4848-4951\nPubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Liu+Zheran%5BAuthor%5D\nGitHub: https://github.com/ZEN-LIU-1\nEmail: zeno.liu@outlook.com"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "ZHERAN LIU",
    "section": "",
    "text": "I am a postdoctoral researcher with training in clinical medicine and oncology (MSc/PhD at West China Hospital) and a bachelor’s degree in Clinical Medicine (Nanchang University). My research interests lie at the intersection of cancer biology, bioinformatics, and clinical translation, with a focus on leveraging multi‑omics and computational methods to derive clinically actionable insights."
  },
  {
    "objectID": "index.html#about",
    "href": "index.html#about",
    "title": "ZHERAN LIU",
    "section": "",
    "text": "I am a postdoctoral researcher with training in clinical medicine and oncology (MSc/PhD at West China Hospital) and a bachelor’s degree in Clinical Medicine (Nanchang University). My research interests lie at the intersection of cancer biology, bioinformatics, and clinical translation, with a focus on leveraging multi‑omics and computational methods to derive clinically actionable insights."
  },
  {
    "objectID": "index.html#highlights",
    "href": "index.html#highlights",
    "title": "ZHERAN LIU",
    "section": "Highlights",
    "text": "Highlights\n\nMulti‑omics / sequencing data analysis for cancer research\nMethod development & reproducible pipelines for translational studies\nOpen to collaboration on clinically grounded bioinformatics projects"
  },
  {
    "objectID": "index.html#news-optional",
    "href": "index.html#news-optional",
    "title": "ZHERAN LIU",
    "section": "News (optional)",
    "text": "News (optional)\n\n2026-02: Homepage scaffold created."
  },
  {
    "objectID": "pages/cv.html",
    "href": "pages/cv.html",
    "title": "CV",
    "section": "",
    "text": "Zheran Liu (刘哲然)\nPostdoctoral Researcher & Physician, Cancer Center, West China Hospital (Sichuan University)\nEmail: mailto:zeno.liu@outlook.com\nORCID: https://orcid.org/0000-0002-4848-4951\nPubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Liu+Zheran%5BAuthor%5D"
  },
  {
    "objectID": "pages/cv.html#education",
    "href": "pages/cv.html#education",
    "title": "CV",
    "section": "Education",
    "text": "Education\n\nPhD/MSc (Oncology; MD–PhD track) — West China School of Medicine / West China Hospital, Sichuan University, China (2019.09–2025.06)\n\nChina Association for Science and Technology (CAST) Young Talent Support Program (PhD track)\nSupervisor: Prof. Xingchen Peng\nHonors/Scholarships (selected): National Scholarship (MOE, China); Abbott Medical Nutrition Scholarship; Daiichi Sankyo Scholarship; Outstanding Graduate Student; Outstanding Graduate\n\nBMed (Clinical Medicine) + Sino‑UK Joint Program (Clinical Medicine & Biomedical Sciences) — Nanchang University, China (2014.09–2019.06)\n\nDual-degree track (Nanchang University × Queen Mary University of London)\nCET‑6: 552"
  },
  {
    "objectID": "pages/cv.html#appointments",
    "href": "pages/cv.html#appointments",
    "title": "CV",
    "section": "Appointments",
    "text": "Appointments\n\nPostdoctoral Researcher & Physician — Cancer Center, West China Hospital (Sichuan University), China (2025.07–present)"
  },
  {
    "objectID": "pages/cv.html#research-interests",
    "href": "pages/cv.html#research-interests",
    "title": "CV",
    "section": "Research interests",
    "text": "Research interests\n\nOncology and cancer bioinformatics\nSequencing / multi‑omics analysis (bulk & single‑cell)\nTranslational research and clinical data integration"
  },
  {
    "objectID": "pages/cv.html#publications-summary",
    "href": "pages/cv.html#publications-summary",
    "title": "CV",
    "section": "Publications (summary)",
    "text": "Publications (summary)\n\nUpdated automatically from OpenAlex using ORCID (0000-0002-4848-4951) on 2026‑02‑04.\n\n\nTotal publications (OpenAlex matched): 157\nH‑index (computed from OpenAlex cited_by_count): 14\nTotal citations (OpenAlex): 775\n\n\nNote: counts can differ from Google Scholar/PubMed due to author disambiguation and indexing coverage."
  },
  {
    "objectID": "pages/cv.html#representative-publications-first-cofirst",
    "href": "pages/cv.html#representative-publications-first-cofirst",
    "title": "CV",
    "section": "Representative publications (first / co‑first)",
    "text": "Representative publications (first / co‑first)\n\nLiu Z. Liquid–liquid phase separation: roles and implications in future cancer treatment. Int J Biol Sci. 2023;19(13):4139–4156. doi:10.7150/ijbs.81521\nLiu Z. Association between fish oil supplementation and cancer risk according to fatty fish consumption: a large prospective cohort study using UK Biobank. Int J Cancer. 2022;150(4):562–571.\nLiu Z. Associations of sleep and circadian phenotypes with COVID‑19 susceptibility and hospitalization: UK Biobank observational cohort + two‑sample Mendelian randomization. Sleep. 2022;45(6):zsac003.\nZhao Y, Liu Z. Biomimetic Hierarchical Construction of Anti‑Tumor Polyoxopalladates for Cancer Therapy. Angew Chem Int Ed. 2025;64(23):e202505564.\n\n\nFull list: see PubMed link above."
  },
  {
    "objectID": "pages/cv.html#patents-filed-selected",
    "href": "pages/cv.html#patents-filed-selected",
    "title": "CV",
    "section": "Patents (filed; selected)",
    "text": "Patents (filed; selected)\n\nUse of mesenchymal stem cell–derived exosomes for treating radiation‑induced skin injury (202410662238.4)\nRadioresistant head and neck squamous cell carcinoma cell line: construction and applications (202410790223.6)\nRadioresistant mouse oral squamous cell carcinoma cell line: construction and applications (202410790222.1)\nUse of SPOP protein for hepatocellular carcinoma therapeutics (202410892129.1)"
  },
  {
    "objectID": "pages/cv.html#grants-projects",
    "href": "pages/cv.html#grants-projects",
    "title": "CV",
    "section": "Grants & projects",
    "text": "Grants & projects\n\nPI — Sichuan Provincial Department of Science and Technology, MZGC20230020: Prognostic model for brain metastasis based on hematological markers (2023‑06‑01 to 2024‑06‑01), 20,000 RMB\nKey participant (lead analyst) — Central Government‑Guided Local S&T Development, 2024ZYD0054: CAF‑mediated EGFR‑TKI resistance in HNSCC (2024‑09‑01 to 2025‑08‑31), 300,000 RMB\nKey participant (lead analyst) — Sichuan International/HK/Macao/Taiwan S&T Collaboration, 2025YFHZ0087: AI‑driven neoantigen prediction & mRNA vaccine development for HNSCC (2025‑01‑01 to 2025‑12‑31), 200,000 RMB\nParticipant — National Key R&D Program of China, 2021YFE0206600: EBV‑targeted mRNA vaccine for nasopharyngeal carcinoma, 1,600,000 RMB (ongoing)"
  },
  {
    "objectID": "pages/cv.html#academic-services",
    "href": "pages/cv.html#academic-services",
    "title": "CV",
    "section": "Academic services",
    "text": "Academic services\n\nEditorial Board Member: BMC Cancer\nGuest Editor: Frontiers in Immunology\nReviewer: The BMJ, iMeta\nMemberships: AACR, Chinese Anti‑Cancer Association\nCommittee roles (selected): Sichuan Medical Communication Society (Cancer Prevention & Control Branch); Chengdu Anti‑Cancer Association (Cancer Rehabilitation)"
  },
  {
    "objectID": "pages/cv.html#training-international-experience",
    "href": "pages/cv.html#training-international-experience",
    "title": "CV",
    "section": "Training & international experience",
    "text": "Training & international experience\n\nASCO Annual Meeting (Chicago), Poster (2024; No. 6046)\nAACR Annual Meeting (Orlando), Poster (2023; No. 5562)\nHarvard & Johns Hopkins Medical School Graduate Training Program (2020)\nQueen Mary University of London, Summer exchange (2016)"
  },
  {
    "objectID": "pages/cv.html#skills",
    "href": "pages/cv.html#skills",
    "title": "CV",
    "section": "Skills",
    "text": "Skills\n\nBioinformatics / data analysis: extensive experience in single‑cell and transcriptomics analysis; clinical research statistics; data mining and visualization in R\nResearch: end‑to‑end experience across basic, translational, and clinical oncology research\nGrant writing / project operations: protocol writing, project registration & submission, statistical analysis"
  },
  {
    "objectID": "pages/cv.html#licenses-certifications",
    "href": "pages/cv.html#licenses-certifications",
    "title": "CV",
    "section": "Licenses & certifications",
    "text": "Licenses & certifications\n\nPhysician License (China)\nGCP Certification"
  },
  {
    "objectID": "pages/projects.html",
    "href": "pages/projects.html",
    "title": "Research",
    "section": "",
    "text": "Oncology and cancer bioinformatics\nSequencing / multi-omics analysis (bulk & single-cell)\nTranslational research and clinical data integration"
  },
  {
    "objectID": "pages/projects.html#research-interests",
    "href": "pages/projects.html#research-interests",
    "title": "Research",
    "section": "",
    "text": "Oncology and cancer bioinformatics\nSequencing / multi-omics analysis (bulk & single-cell)\nTranslational research and clinical data integration"
  },
  {
    "objectID": "pages/projects.html#selected-grants-projects",
    "href": "pages/projects.html#selected-grants-projects",
    "title": "Research",
    "section": "Selected grants & projects",
    "text": "Selected grants & projects\n\nPI — Sichuan Provincial Department of Science and Technology, MZGC20230020: Prognostic model for brain metastasis based on hematological markers (2023-06-01 to 2024-06-01), 20,000 RMB\nKey participant (lead analyst) — Central Government-Guided Local S&T Development, 2024ZYD0054: CAF-mediated EGFR-TKI resistance in HNSCC (2024-09-01 to 2025-08-31), 300,000 RMB\nKey participant (lead analyst) — Sichuan International/HK/Macao/Taiwan S&T Collaboration, 2025YFHZ0087: AI-driven neoantigen prediction & mRNA vaccine development for HNSCC (2025-01-01 to 2025-12-31), 200,000 RMB\nParticipant — National Key R&D Program of China, 2021YFE0206600: EBV-targeted mRNA vaccine for nasopharyngeal carcinoma (ongoing), 1,600,000 RMB"
  },
  {
    "objectID": "pages/projects.html#software-code",
    "href": "pages/projects.html#software-code",
    "title": "Research",
    "section": "Software / code",
    "text": "Software / code\n\nGitHub: https://github.com/ZEN-LIU-1\n\n\nIf you want this page to look more like a “research portfolio”, tell me 3–5 representative projects you want highlighted (title + 1–2 lines each + optional link), and I’ll format it."
  }
]